FOXP3 Expression Control Modulation for Treg Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for generating regulatory T cells (Tregs) for autoimmune disease treatment often fail to achieve sustained expression of genes leading to a suppression phenotype, limiting their therapeutic effectiveness.
Innovation Solution
The development of site-specific FOXP3 disrupting agents that target the FOXP3 expression control region using polymeric molecules, polynucleotides, or peptide nucleic acids to modulate FOXP3 expression, enhancing or reducing its levels in mammalian cells, including naïve T cells, to promote the differentiation of Tregs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current strategies are used to generate regulatory T cells (Tregs) for autoimmune disease treatment, then Tregs can be produced, but they fail to achieve sustained expression of genes leading to suppression phenotype
Solution Approach 1:
The patent introduces FOXP3 expression control regions (such as enhancers or promoters) into the Treg cells before their therapeutic application. This preliminary genetic modification ensures that the Tregs are pre-equipped with the necessary regulatory elements to sustain FOXP3 expression and suppression phenotype throughout their therapeutic function, rather than attempting to restore expression after it has been lost.
2Stability of the object's composition
If FOXP3 expression is not sustained in Tregs, then Tregs can be generated, but they do not maintain suppression phenotype
Solution Approach 1:
The patent applies local quality by specifically targeting the FOXP3 gene's expression control regions (enhancers, promoters, or other regulatory elements) rather than attempting to modify the entire Treg cell or all genes simultaneously. This focused approach ensures that the suppression phenotype is stabilized through precise modification of the specific genetic elements that control FOXP3 expression, thereby maintaining the critical local function of Tregs.
3Productivity
If current Treg generation methods are used, then Tregs can be produced for therapy, but they lack sustained gene expression leading to limited therapeutic effectiveness
Solution Approach 1:
The patent ensures continuity of useful action by introducing stable, long-term expression control elements (such as integrated enhancers or promoters) that maintain FOXP3 expression continuously throughout the lifespan of the Treg cells. This continuous expression ensures that the therapeutic action of the Tregs—suppressing autoimmune responses—remains effective over extended periods, rather than being transient or intermittent.
Data Source
AI summary
The present invention provides agents and compositions for modulating expression (e.g., enhanced or reduced expression) of a forkhead box P3 (FOXP3) gene by targeting a FOXP3 expression control region and methods of use thereof for treating a FOXP3 associated disorder, such as an autoimmune disease, e.g., IPEX syndrome.